ArticleCase reports in hematology2026
Extranodal Nasal Type NK/T-Cell Lymphoma of the Transverse Colon With Gastrointestinal Perforation in a 15-Year-Old: Durable Remission With Modified SMILE Chemotherapy and HSCT.
Article in Case reports in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NK/T-cell lymphoma (NKTCL) is an aggressive lymphoma associated with Epstein-Barr virus (EBV), with higher incidence in Asian populations. Typically, patients present in their fifth decade with extranodal disease in the upper aerodigestive tract. Pediatric NKTCL is rare, with no established pediatric standard of care treatment. We describe the case of a healthy 15-year-old Filipino-Canadian male who presented with transverse colon perforation and was diagnosed with extranodal EBV + nasal type NKTCL of the gastrointestinal (GI) tract. After a complicated initial surgical course, we elected to treat him using six cycles of modified SMILE (dexamethasone, PEG-asparaginase, ifosfamide, and etoposide) chemotherapy and consolidative hematopoietic stem cell transplant (HSCT). The post-HSCT course involved cytomegalovirus reactivation (buccal lesions, viremia); adenovirus reactivation (positive nasal swab, viremia); zoster reactivation; acute and chronic oral/upper GI graft-versus-host disease (GVHD); chronic skin GVHD (vitiligo); and avascular necrosis. At the most recent follow-up, surveillance imaging and investigations at 2 years post-transplant showed durable CR1 and 100% donor chimerism. To our knowledge, this is the fourth reported case of primary GI NKTCL in a pediatric/adolescent patient; the only patient treated with an asparaginase-containing regimen; and the only patient to undergo consolidative HSCT. Our patient's outcome supports the utilization of an aggressive approach to treat GI NKTCL in young, fit patients similar to Stage III/VI nasal NKTCL. Our case also highlights unique treatment considerations for adolescent cancer patients, including delayed diagnoses and lack of standardized protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.